Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
Drug Saf
    June 2025
  1. ROQUE-PEREIRA L, Sisay MM, Ogar CK, Duran CE, et al
    Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.
    Drug Saf. 2025 Jun 10. doi: 10.1007/s40264-025-01561.
    >> Share

    May 2025
  2. HAMZAOUI H, Shaum A, Cherkaoui I, Moussa LA, et al
    Assessment of Pharmacovigilance Across University Hospitals in Morocco.
    Drug Saf. 2025;48:527-539.
    >> Share

    March 2025
  3. NAMBASA VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, et al
    Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group.
    Drug Saf. 2025;48:233-249.
    >> Share

  4. BOULEFAA D, Bagheri H, Salvo F, Rabier MB, et al
    Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Drug Saf. 2025;48:251-263.
    >> Share

    November 2024
  5. MORCIANO C, Massari M, Cutillo M, Belleudi V, et al
    Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study.
    Drug Saf. 2024;47:1157-1169.
    >> Share

    October 2024
  6. CIAPPONI A, Berrueta M, Argento FJ, Ballivian J, et al
    Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
    Drug Saf. 2024;47:991-1010.
    >> Share

  7. YAN VKC, Yang Y, Wan EYF, Lai FTT, et al
    Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Drug Saf. 2024;47:1025-1037.
    >> Share

  8. BELLITTO C, Luxi N, Ciccimarra F, L'Abbate L, et al
    What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Drug Saf. 2024;47:1011-1023.
    >> Share

    September 2024
  9. WYSZYNSKI DF, Demetriou L, Renz C, Aliabadi S, et al
    Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.
    Drug Saf. 2024;47:843-851.
    >> Share

    August 2024
  10. GORDILLO-MARANON M, Szmigiel A, Yalmanova V, Caplanusi I, et al
    COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance.
    Drug Saf. 2024;47:783-798.
    >> Share

    July 2024
  11. GORDILLO-MARANON M, Candore G, Hedenmalm K, Browne K, et al
    Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.
    Drug Saf. 2024;47:607-615.
    >> Share

    June 2024
  12. DE LA CUEVA IS, Gerber JE, Hastie A, Brotons C, et al
    Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    Drug Saf. 2024 Jun 29. doi: 10.1007/s40264-024-01456.
    >> Share

    May 2024
  13. CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al
    The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
    Drug Saf. 2024;47:405-418.
    >> Share

    March 2024
  14. DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al
    An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged
    Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395.
    >> Share

  15. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
    The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
    Drug Saf. 2024;47:195-204.
    >> Share

    February 2024
  16. MORO PL, Ennulat C, Brown H, Woody G, et al
    Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406.
    >> Share

  17. QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al
    Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
    Drug Saf. 2024;47:135-146.
    >> Share

  18. DONG G, Bate A, Haguinet F, Westman G, et al
    Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Drug Saf. 2024;47:173-182.
    >> Share

    December 2023
  19. DE GERMAY S, Singier A, Salvo F, Pariente A, et al
    Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    Drug Saf. 2023;46:1381-1389.
    >> Share

    November 2023
  20. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al
    An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
    Drug Saf. 2023;46:1089-1103.
    >> Share

    October 2023
  21. SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al
    The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356.
    >> Share

    September 2023
  22. WALTON M, Pletzer V, Teunissen T, Lumley T, et al
    Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Drug Saf. 2023;46:867-879.
    >> Share

    June 2023
  23. KAUR U, Fatima Z, Maheshwari K, Sahni V, et al
    Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Drug Saf. 2023;46:553-563.
    >> Share

  24. AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al
    Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Drug Saf. 2023;46:575-585.
    >> Share

    May 2023
  25. KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al
    Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error Data.
    Drug Saf. 2023;46:501-507.
    >> Share

    April 2023
  26. BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al
    Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
    Drug Saf. 2023;46:327-333.
    >> Share

  27. RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al
    Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Drug Saf. 2023;46:391-404.
    >> Share

  28. OGAR CK, Quick J, Gilbert HN, Vreman RA, et al
    Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Drug Saf. 2023;46:357-370.
    >> Share

    March 2023
  29. KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.
    Drug Saf. 2023;46:319-321.
    >> Share

  30. WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al
    The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.
    Drug Saf. 2023;46:297-308.
    >> Share

  31. ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al
    Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
    Drug Saf. 2023;46:273-281.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016